Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 437

1.

Plasma miRNA-based signatures in CRC screening programs.

Zanutto S, Ciniselli CM, Belfiore A, Lecchi M, Masci E, Delconte G, Primignani M, Tosetti G, Dal Fante M, Fazzini L, Airoldi A, Vangeli M, Turpini F, Rubis Passoni GG, Viaggi P, Arena M, Motta RIO, Cantù AM, Crosta C, De Roberto G, Iannuzzi F, Cassinotti A, Dall'Olio V, Tizzoni L, Sozzi G, Meroni E, Bisanti L, Pierotti MA, Verderio P, Gariboldi M.

Int J Cancer. 2019 Jul 15. doi: 10.1002/ijc.32573. [Epub ahead of print]

PMID:
31304978
2.

Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production.

Mogavero A, Maiorana MV, Zanutto S, Varinelli L, Bozzi F, Belfiore A, Volpi CC, Gloghini A, Pierotti MA, Gariboldi M.

Sci Rep. 2017 Nov 22;7(1):15992. doi: 10.1038/s41598-017-16149-z.

3.

Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research.

Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, Stanta G; On the behalf of the “dynamic medicine OECI group”.

J Exp Clin Cancer Res. 2017 Sep 13;36(1):128. doi: 10.1186/s13046-017-0598-x. Review.

4.

The molecular understanding of cancer: from the unspeakable illness to a curable disease.

Pierotti MA.

Ecancermedicalscience. 2017 Jun 8;11:747. doi: 10.3332/ecancer.2017.747. eCollection 2017.

5.

MIF/CD74 axis is a target for novel therapies in colon carcinomatosis.

Bozzi F, Mogavero A, Varinelli L, Belfiore A, Manenti G, Caccia C, Volpi CC, Beznoussenko GV, Milione M, Leoni V, Gloghini A, Mironov AA, Leo E, Pilotti S, Pierotti MA, Bongarzone I, Gariboldi M.

J Exp Clin Cancer Res. 2017 Jan 23;36(1):16. doi: 10.1186/s13046-016-0475-z.

6.

Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumours.

Spagnuolo RD, Brich S, Bozzi F, Conca E, Castelli C, Tazzari M, Maestro R, Brenca M, Gualeni AV, Gloghini A, Stacchiotti S, Pierotti MA, Pilotti S, Negri T.

Oncotarget. 2016 Jul 19;7(29):45015-45026. doi: 10.18632/oncotarget.7523.

7.

Whole exome sequencing and single nucleotide polymorphism array analyses to identify germline alterations in genes associated with testosterone metabolism in a patient with androgen insensitivity syndrome and early-onset colorectal cancer.

Disciglio V, Devecchi A, Palumbo O, Carella M, Penso D, Milione M, Valle G, Pierotti MA, Vitellaro M, Bertario L, Canevari S, Signoroni S, De Cecco L.

Chin J Cancer. 2016 Jun 7;35(1):51. doi: 10.1186/s40880-016-0115-1.

8.

Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc.

Roccato E, Miranda C, Ranzi V, Gishizki M, Pierotti MA, Greco A.

Br J Cancer. 2016 Jun 14;114(12):e19. doi: 10.1038/bjc.2016.131. Epub 2016 May 26. No abstract available.

9.

miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.

Crippa E, Folini M, Pennati M, Zaffaroni N, Pierotti MA, Gariboldi M.

Oncotarget. 2016 Apr 5;7(14):18594-604. doi: 10.18632/oncotarget.7617.

10.

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Pinciroli P, Won H, Iyer G, Canevari S, Colecchia M, Giannatempo P, Raggi D, Pierotti MA, De Braud FG, Solit DB, Rosenberg JE, Berger MF, Necchi A.

Clin Genitourin Cancer. 2016 Feb;14(1):e81-90. doi: 10.1016/j.clgc.2015.07.017. Epub 2015 Aug 7. No abstract available.

11.

FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.

Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM; GENESIS, Mitchell G, James PA, Thompson E; kConFab; SWE-BRCA, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della Puppa L, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M, Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivanet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmaña J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lázaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P.

Hum Mol Genet. 2015 Sep 15;24(18):5345-55. doi: 10.1093/hmg/ddv251. Epub 2015 Jun 30.

12.

Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation.

Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, Gronchi A, Stacchiotti S, Pierotti MA, Negri T, Pilotti S.

Mod Pathol. 2015 Aug;28(8):1074-83. doi: 10.1038/modpathol.2015.70. Epub 2015 May 29.

13.

The Effects of miR-20a on p21: Two Mechanisms Blocking Growth Arrest in TGF-β-Responsive Colon Carcinoma.

Sokolova V, Fiorino A, Zoni E, Crippa E, Reid JF, Gariboldi M, Pierotti MA.

J Cell Physiol. 2015 Dec;230(12):3105-14. doi: 10.1002/jcp.25051.

PMID:
26012475
14.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Jun 10;6(16):14139-52.

15.

The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies.

Colombo C, Minna E, Rizzetti MG, Romeo P, Lecis D, Persani L, Mondellini P, Pierotti MA, Greco A, Fugazzola L, Borrello MG.

Orphanet J Rare Dis. 2015 Mar 1;10:25. doi: 10.1186/s13023-015-0231-z.

16.

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.

Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, de Braud F, Clementi E, Pietrantonio F.

Br J Clin Pharmacol. 2015 Sep;80(3):581-8. doi: 10.1111/bcp.12631. Epub 2015 Jun 22.

17.

Moving from discovery to validation in circulating microRNA research.

Verderio P, Bottelli S, Ciniselli CM, Pierotti MA, Zanutto S, Gariboldi M, Pizzamiglio S.

Int J Biol Markers. 2015 May 26;30(2):e258-61. doi: 10.5301/jbm.5000135.

PMID:
25704507
18.

Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.

Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, Bossi P, Gloghini A, Gualeni AV, Volpi CC, Locati L, Pierotti MA, Licitra L, Pilotti S, Perrone F.

J Oral Pathol Med. 2015 Oct;44(9):734-45. doi: 10.1111/jop.12301. Epub 2014 Dec 14.

PMID:
25495427
19.

Gene expression profiling of circulating tumor cells in breast cancer.

Fina E, Callari M, Reduzzi C, D'Aiuto F, Mariani G, Generali D, Pierotti MA, Daidone MG, Cappelletti V.

Clin Chem. 2015 Jan;61(1):278-89. doi: 10.1373/clinchem.2014.229476. Epub 2014 Nov 19.

20.

Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved.

Vizioli MG, Santos J, Pilotti S, Mazzoni M, Anania MC, Miranda C, Pagliardini S, Pierotti MA, Gil J, Greco A.

Oncotarget. 2014 Sep 30;5(18):8270-83.

21.

Identification of a gene expression driven progression pathway in myxoid liposarcoma.

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G, Disciglio V, Sanfilippo R, Gronchi A, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S.

Oncotarget. 2014 Aug 15;5(15):5965-77.

22.

Functional characterization of NTRK1 mutations identified in melanoma.

Miranda C, Mazzoni M, Sensi M, Pierotti MA, Greco A.

Genes Chromosomes Cancer. 2014 Oct;53(10):875-80. doi: 10.1002/gcc.22200. Epub 2014 Jun 26.

PMID:
24965840
23.

The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, Amboldi N, Raddrizzani L, Milani A, Magnaghi P, Ballinari D, Casero D, Gasparri F, Banfi P, Avanzi N, Saccardo MB, Alzani R, Bandiera T, Felder E, Donati D, Pesenti E, Sartore-Bianchi A, Gambacorta M, Pierotti MA, Siena S, Veronese S, Galvani A, Isacchi A.

Mol Oncol. 2014 Dec;8(8):1495-507. doi: 10.1016/j.molonc.2014.06.001. Epub 2014 Jun 12.

24.

NqA: an R-based algorithm for the normalization and analysis of microRNA quantitative real-time polymerase chain reaction data.

Verderio P, Bottelli S, Ciniselli CM, Pierotti MA, Gariboldi M, Pizzamiglio S.

Anal Biochem. 2014 Sep 15;461:7-9. doi: 10.1016/j.ab.2014.05.020. Epub 2014 Jun 2.

PMID:
24892985
25.

Circulating free DNA in a screening program for early colorectal cancer detection.

Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni E, Leo E, Pierotti MA, Pilotti S.

Tumori. 2014 Mar-Apr;100(2):115-21. doi: 10.1700/1491.16389.

PMID:
24852853
26.

Reply to What if axillary lymph node dissection became less fashionable?

Agresti R, Martelli G, Sandri M, Pierotti MA.

Cancer. 2014 Aug 15;120(16):2535-6. doi: 10.1002/cncr.28770. Epub 2014 May 20. No abstract available.

27.

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.

Minna E, Romeo P, De Cecco L, Dugo M, Cassinelli G, Pilotti S, Degl'Innocenti D, Lanzi C, Casalini P, Pierotti MA, Greco A, Borrello MG.

Oncotarget. 2014 May 15;5(9):2513-28.

28.

miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.

Crippa E, Lusa L, De Cecco L, Marchesi E, Calin GA, Radice P, Manoukian S, Peissel B, Daidone MG, Gariboldi M, Pierotti MA.

PLoS One. 2014 Jan 27;9(1):e87039. doi: 10.1371/journal.pone.0087039. eCollection 2014.

29.

Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer.

Zanutto S, Pizzamiglio S, Ghilotti M, Bertan C, Ravagnani F, Perrone F, Leo E, Pilotti S, Verderio P, Gariboldi M, Pierotti MA.

Br J Cancer. 2014 Feb 18;110(4):1001-7. doi: 10.1038/bjc.2013.819. Epub 2014 Jan 14.

30.

Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies.

Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, Gronchi A, Panizza P, Pierotti MA, Tamborini E, Pilotti S.

Neuro Oncol. 2014 Jan;16(1):72-80. doi: 10.1093/neuonc/not238.

31.

Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).

Agresti R, Martelli G, Sandri M, Tagliabue E, Carcangiu ML, Maugeri I, Pellitteri C, Ferraris C, Capri G, Moliterni A, Bianchi G, Mariani G, Trecate G, Lozza L, Langer M, Rampa M, Gennaro M, Greco M, Menard S, Pierotti MA.

Cancer. 2014 Mar 15;120(6):885-93. doi: 10.1002/cncr.28499. Epub 2013 Dec 5.

32.

A normalization strategy for the analysis of plasma microRNA qPCR data in colorectal cancer.

Pizzamiglio S, Bottelli S, Ciniselli CM, Zanutto S, Bertan C, Gariboldi M, Pierotti MA, Verderio P.

Int J Cancer. 2014 Apr 15;134(8):2016-8. doi: 10.1002/ijc.28530. Epub 2013 Oct 22. No abstract available.

33.

The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers.

Borreani C, Manoukian S, Bianchi E, Brunelli C, Peissel B, Caruso A, Morasso G, Pierotti MA.

Clin Genet. 2014 Jan;85(1):7-15. doi: 10.1111/cge.12298. Epub 2013 Nov 5.

PMID:
24117034
34.

Frequent mutation and nuclear localization of β-catenin in sertoli cell tumors of the testis.

Perrone F, Bertolotti A, Montemurro G, Paolini B, Pierotti MA, Colecchia M.

Am J Surg Pathol. 2014 Jan;38(1):66-71. doi: 10.1097/PAS.0b013e31829cdbc6.

PMID:
24061522
35.

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

36.

S100A11 overexpression contributes to the malignant phenotype of papillary thyroid carcinoma.

Anania MC, Miranda C, Vizioli MG, Mazzoni M, Cleris L, Pagliardini S, Manenti G, Borrello MG, Pierotti MA, Greco A.

J Clin Endocrinol Metab. 2013 Oct;98(10):E1591-600. doi: 10.1210/jc.2013-1652. Epub 2013 Aug 8.

PMID:
23928665
37.

miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts.

Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, Valdagni R, Pierotti MA, Zaffaroni N, Chiarugi P.

Antioxid Redox Signal. 2014 Mar 1;20(7):1045-59. doi: 10.1089/ars.2013.5292. Epub 2013 Sep 17.

38.

Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.

Conca E, Miranda C, Dal Col V, Fumagalli E, Pelosi G, Mazzoni M, Fermeglia M, Laurini E, Pierotti MA, Pilotti S, Greco A, Pricl S, Tamborini E.

Mol Oncol. 2013 Aug;7(4):756-62. doi: 10.1016/j.molonc.2013.02.019. Epub 2013 Mar 21.

39.

A review on biomarkers for prediction of treatment outcome in gastric cancer.

Pietrantonio F, De Braud F, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M.

Anticancer Res. 2013 Apr;33(4):1257-66. Review.

PMID:
23564763
40.

RET inhibition: implications in cancer therapy.

Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA.

Expert Opin Ther Targets. 2013 Apr;17(4):403-19. doi: 10.1517/14728222.2013.758715. Epub 2013 Mar 6. Review.

PMID:
23461584
41.

Effects of warm ischemic time on gene expression profiling in colorectal cancer tissues and normal mucosa.

Musella V, Verderio P, Reid JF, Pizzamiglio S, Gariboldi M, Callari M, Milione M, De Cecco L, Veneroni S, Pierotti MA, Daidone MG.

PLoS One. 2013;8(1):e53406. doi: 10.1371/journal.pone.0053406. Epub 2013 Jan 7. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/11071e0f-4f09-4b1f-93ec-f1362610ce33. Massimo, Milione [corrected to Milione, Massimo].

42.

DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.

Degl'Innocenti D, Romeo P, Tarantino E, Sensi M, Cassinelli G, Catalano V, Lanzi C, Perrone F, Pilotti S, Seregni E, Pierotti MA, Greco A, Borrello MG.

Endocr Relat Cancer. 2013 Jan 21;20(1):23-37. doi: 10.1530/ERC-12-0078. Print 2013 Feb.

PMID:
23132790
43.

Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues.

Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L.

PLoS One. 2012;7(9):e45105. doi: 10.1371/journal.pone.0045105. Epub 2012 Sep 13. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/c38405cc-dc33-424e-bfcb-14de73f5c8c8.

44.

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.

Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S.

Oncogene. 2013 Mar 21;32(12):1475-87. doi: 10.1038/onc.2012.181. Epub 2012 Jun 4. Review.

PMID:
22665053
45.

miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation.

Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M, Pierotti MA.

Mol Cancer Res. 2012 Apr;10(4):504-15. doi: 10.1158/1541-7786.MCR-11-0342. Epub 2012 Feb 16.

46.

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.

Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M.

Clin Cancer Res. 2012 Mar 15;18(6):1769-76. doi: 10.1158/1078-0432.CCR-11-2230. Epub 2012 Jan 26.

47.

Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.

Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, Gronchi A, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S.

Genes Chromosomes Cancer. 2012 Feb;51(2):111-26. doi: 10.1002/gcc.20933. Epub 2011 Nov 1.

PMID:
22045652
48.

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.

Da Riva L, Bozzi F, Mondellini P, Miccichè F, Fumagalli E, Vaghi E, Tarantino E, Huber V, Gronchi A, Tamborini E, Pierotti MA, Pilotti S, Bongarzone I.

J Transl Med. 2011 Sep 23;9:158. doi: 10.1186/1479-5876-9-158.

49.

Evidence of oncogene-induced senescence in thyroid carcinogenesis.

Vizioli MG, Possik PA, Tarantino E, Meissl K, Borrello MG, Miranda C, Anania MC, Pagliardini S, Seregni E, Pierotti MA, Pilotti S, Peeper DS, Greco A.

Endocr Relat Cancer. 2011 Dec 1;18(6):743-57. doi: 10.1530/ERC-11-0240. Print 2011 Dec.

PMID:
21937739
50.

Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.

Borrello MG, Aiello A, Peissel B, Rizzetti MG, Mondellini P, Degl'Innocenti D, Catalano V, Gobbo M, Collini P, Bongarzone I, Pierotti MA, Greco A, Seregni E.

Endocr Relat Cancer. 2011 Jul 25;18(4):519-27. doi: 10.1530/ERC-10-0306. Print 2011 Aug.

PMID:
21690267

Supplemental Content

Loading ...
Support Center